Flumazenil

Reversal of benzodiazepine sedation

Used to reverse the sedative effects of benzodiazepines given for general anesthesia or for diagnostic/therapeutic (conscious sedation) procedures, in adults and in pediatric patients aged 1 to 17 years. (2)

Management of benzodiazepine overdose

Used in adults for the management of known or suspected benzodiazepine overdose, to reverse sedation and respiratory depression under close clinical monitoring. (2)

Differential diagnosis of coma of unknown etiology (when benzodiazepine overdose is suspected)

Sometimes used diagnostically in adults with unexplained coma when benzodiazepine involvement is suspected, to help distinguish benzodiazepine-related sedation from other causes. (2)

Reversal of benzodiazepine-induced respiratory depression

Used to help restore adequate breathing when benzodiazepine sedation has caused respiratory depression, always with continued monitoring since flumazenil's effects can wear off before the benzodiazepine is cleared. (2)

Nausea/vomiting

Incidence: About 11% (per FDA label)

Agitation/anxiety

Incidence: About 3%-9% (per FDA label)

Dizziness

Incidence: About 3%-9% (per FDA label)

Injection site pain

Incidence: About 3%-9% (per FDA label)

Headache

Incidence: About 3%-9% (per FDA label)

Blurred or abnormal vision

Incidence: About 1%-9% (per FDA label)

Emotional lability, paresthesia

Incidence: About 1%-3% (per FDA label)

Seizures (most frequent in patients on long-term benzodiazepine therapy or in cyclic antidepressant overdose) — this is an FDA boxed-warning-level risk

Incidence: Less than 1%, but serious

Confusion, unusual sleepiness (somnolence), or irregular heartbeat (cardiac dysrhythmia)

Incidence: Less than 1%, but serious

FDA BOXED WARNING (the label's highest-level safety warning) — serious

Symptoms: FDA BOXED WARNING (the label's highest-level safety warning): the use of flumazenil has been associated with seizures. Seizures are most frequent in patients who have been on benzodiazepines for long-term sedation, or in overdose cases where the patient is showing signs of serious cyclic (tricyclic) antidepressant overdose. This risk requires flumazenil to be given only by trained healthcare professionals with resuscitation equipment and seizure management immediately available.

Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)

May cause withdrawal symptoms in patients dependent on benzodiazepines — serious

Symptoms: May cause withdrawal symptoms in patients dependent on benzodiazepines. Monitor for resedation after administration, since flumazenil's effects may wear off before the benzodiazepine is fully cleared. Not effective for non-benzodiazepine overdoses. Use with caution in patients with head injury or increased intracranial pressure.

Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)

The formal FDA contraindications are — serious

Symptoms: The formal FDA contraindications are: known hypersensitivity to flumazenil or to benzodiazepines; use in patients who have received a benzodiazepine to control a potentially life-threatening condition (e.g., status epilepticus, increased intracranial pressure); and signs of a serious cyclic (tricyclic) antidepressant overdose. Clinicians also use added caution in patients with seizure disorders, mixed drug overdose, or hepatic impairment.

Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)

Pregnancy

FDA Pregnancy Category C: flumazenil should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; there are no adequate, well-controlled studies in pregnant women. Any use in pregnancy is a decision for the treating clinical team based on the emergency or procedural need. (2)

Breastfeeding

It is not known whether flumazenil passes into human breast milk. Caution is advised when deciding whether to give flumazenil to a nursing woman, and the care team can advise on breastfeeding timing afterward. (2)

Children

Flumazenil IS approved for reversal of benzodiazepine-induced conscious sedation in pediatric patients aged 1 to 17 years, using weight-based dosing (0.01 mg/kg IV, up to 0.2 mg, repeatable at 60-second intervals to a maximum of 0.05 mg/kg or 1 mg total, whichever is lower). Safety and efficacy have NOT been established in children under 1 year of age, and the risk of resedation is specifically higher in children aged 1-5 years, so close monitoring is essential. Use for benzodiazepine-overdose reversal in children is not an established pediatric indication. (2)

Renal_impairment

Hepatic impairment: clearance is reduced to about 40%-60% of normal in moderate hepatic dysfunction (half-life around 1.3 hours) and to about 25% of normal in severe dysfunction (half-life around 2.4 hours); the first reversal dose is generally unaffected, but repeat-dose size and frequency are reduced by the clinical team in significant liver disease. Renal impairment: pharmacokinetics are not significantly affected by renal failure. (2)

Hepatic_impairment

Hepatic impairment: clearance is reduced to about 40%-60% of normal in moderate hepatic dysfunction (half-life around 1.3 hours) and to about 25% of normal in severe dysfunction (half-life around 2.4 hours); the first reversal dose is generally unaffected, but repeat-dose size and frequency are reduced by the clinical team in significant liver disease. Renal impairment: pharmacokinetics are not significantly affected by renal failure. (2)

India

• FlumaconFlagship Biotech International
• FludotNeon Laboratories Ltd